You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
The firm saw modest growth in both its life science and diagnostics divisions and increased its guidance for the year.
The firm saw double-digit growth in both its core diagnostics and life sciences businesses, with losses in its Magellan lead testing division.
The firm saw a 6 percent increase in fiscal fourth quarter revenues, with growth in both its diagnostics and life science segments.
The firm attributes the positive results to efforts to strengthen its US diagnostics business and stabilize its core diagnostics product families of H. pylori and food testing.
The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent.
This week's news on Quest Diagnostics, Agilent Technologies, Meridian Bioscience, Era7, DermTech, and Source Molecular.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
The company's second quarter revenue growth was driven in part by strong sales from its life science segment.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
In Nature this week: the largest known collection of human genetic variants, and more.